Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
AICA-ribosiduria is an extremely severe inborn error of purine biosynthesis characterized clinically in the single reported case to date by profound intellectual deficit, epilepsy, dysmorphic features of the knees, elbows, and shoulders and congenital blindness.
Features include always present findings: Anteverted nares, Profound intellectual disability, Elevated erythrocyte AICA-ribotide concentration, and Low muscle tone (hypotonia) and others; and very common findings: Seizure, Fused labia minora, Prominent forehead, and Thin upper lip vermilion and others. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Seizure, Profound intellectual disability, Severe intellectual disability |
ATIC encodes 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (592 aa). Bifunctional enzyme that catalyzes the last two steps of purine biosynthesis. Highest expression in Cells EBV-transformed lymphocytes (154.0 TPM) and Cells Cultured fibroblasts (101.0 TPM).
AICA-ribosiduria is associated with mutations in the ATIC gene on chromosome 2.
The ATIC protein participates in ATIC(1-230)-ALK(1059-1620) fusion, ATIC(1-229)-ALK(1058-1620) fusion, and ATIC(1-230)-p-7Y-ALK(1059-1620) fusion pathways.
ATIC is classified as a druggable target (Clinically Actionable, Druggable Genome, and Enzyme categories) with score 1.6.
Genetic testing for ATIC is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 13 always present features, 10 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
4 publications have been identified in PubMed for AICA-ribosiduria. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Shi Y (2025). [PMID: 40217360](https://pubmed.ncbi.nlm.nih.gov/40217360/). *Acta epileptologica*. [Review / Meta-Analysis]
Weng WC (2025). [PMID: 39604553](https://pubmed.ncbi.nlm.nih.gov/39604553/). *European journal of human genetics : EJHG*. [Case Report / Case Series]
Peng Z (2025). [PMID: 40623538](https://pubmed.ncbi.nlm.nih.gov/40623538/). *Free radical biology & medicine*. [Basic Science / Preclinical]
Shi X (2024). [PMID: 39129491](https://pubmed.ncbi.nlm.nih.gov/39129491/). *American journal of physiology. Cell physiology*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 11:21 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about AICA-ribosiduria
Muscles | 2 | Low muscle tone (hypotonia), Damage to the optic nerve (optic atrophy) |
Eyes | 2 | Damage to the optic nerve (optic atrophy), Congenital blindness |
Head and neck | 1 | Thin upper lip vermilion |
Heart and blood vessels | 1 | Secundum atrial septal defect |
Kidneys and urinary system | 1 | Elevated urinary 5-amino-4-imidazolecarboxamide-riboside level |
Skin | 1 | Skin dimple |
Pregnancy and birth | 1 | Congenital blindness |